Prosetta, BMS form multi-year antiviral drug development collaboration

Wednesday, August 1, 2012 01:56 PM

Prosetta Antiviral, a San Francisco-based biotechnology company, has formed a strategic alliance with global biopharmaceutical company Bristol-Myers Squibb (BMS) to further discover and develop select drug candidates representing new, novel classes of antiviral drugs.

Currently, Prosetta has a portfolio comprising novel chemical classes of small molecules with antiviral activity which target catalytic host protein interactions essential for the virus, but not the host. These molecules represent a new therapeutic approach for antiviral agents.

The collaboration will include a research program focused on the discovery and advancement of compounds shown to block viral capsid assembly using Prosetta’s proprietary drug discovery platform. BMS will have the right to develop and commercialize products arising from the research program.

Prosetta will receive an upfront payment and multi-year research funding. The company is also eligible to receive milestone payments and royalties based on worldwide sales of the drugs emerging from the collaboration.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 21

Healthcare IPOs soar in first quarter

Survey compares 'push/pull' tactics in patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs